Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study on the Safety and Efficacy of Adenosylcobalamin in Patients With Declining Ovarian Function

18. november 2026 opdateret af: Shixuan Wang, Tongji Hospital

The goal of this clinical trial is to learn if adenosylcobalamin works to treat POI and DOR. It will also learn about the safety of adenosylcobalamin. The main questions it aims to answer are:

Can adenosylcobalamin improve the clinical symptoms, signs, and hormone levels of patients with POI and DOR? What is the safety of adenosylcobalamin?

Participants will:

Take adenosylcobalamin three times a day for 3 months Visit the clinic for 5 checkups and tests

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

48

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 39 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  1. Premature Ovarian Insufficiency (POI): Age < 40 years old, with two consecutive basal FSH levels ≥ 25 U/L spaced 4 weeks apart, decreased anti-müllerian hormone (AMH), and clinical manifestations of oligomenorrhea or amenorrhea.

(2) Diminished ovarian reserve (DOR): Age < 40 years old, with a decrease in the number and/or quality of oocytes in the ovary, and/or accompanied by a decreased AMH level (< 1.1 ng/mL), and/or a reduced number of antral follicles (AFC) (< 6) and/or an elevated basal FSH level (> 10 U/L).

Exclusion Criteria:

  1. Abnormal uterine bleeding of unknown cause;
  2. Presence of ovarian/appendage masses ≥ 4 cm, uterine adenomyosis, uterine adenomyoma/uterine fibroids ≥ 4 cm;
  3. BI-RADS rating of breast ultrasound ≥ 4;
  4. Presence of precancerous lesions or having malignant tumors;
  5. Liver and kidney function indicators (ALT, AST, Urea, Cr) exceed the upper limit of normal reference values and have not returned to normal after re-examination;
  6. Complicated with severe primary diseases in the nervous, circulatory, respiratory, digestive, urinary or hematopoietic systems, or patients with mental disorders;
  7. Have received systemic hormone replacement therapy within the last 2 months;
  8. Are participating in other clinical trials or have participated in other clinical trials within the last 1 month;
  9. Have a recent fertility requirement;
  10. Other patients deemed unsuitable for participation in this study by the researchers.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: POI and DOR

Take oral adenosylcobalamin tablets, 0.5mg per dose, three times a day. Continue the treatment for 12 weeks.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
anti-müllerianhormone
Tidsramme: Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.

The serum anti-müllerianhormone(AMH) level is the primary indicator for evaluating ovarian reserve function and is used for diagnosing POI and DOR. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function.

Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
sex hormones
Tidsramme: Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.

The sex hormone tests include estradiol, follicle-stimulating hormone(FSH), luteinizing hormone(LH), progesterone, testosterone and prolactin. Among them, FSH is the main indicator for diagnosing POI and DOR. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function.

Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.
antral follicles
Tidsramme: Color Doppler ultrasound examination will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.

The number of antral follicles refers to the total count of antral follicles observed bilaterally in the ovaries through transvaginal ultrasound examination during the early stage of follicular development. Studies have confirmed that the number of antral follicles is related to the size of the primordial follicle pool, and it can be used to assess ovarian reserve function. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function.

Color Doppler ultrasound examination will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

20. november 2026

Primær færdiggørelse (Anslået)

31. juli 2027

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

13. november 2026

Først indsendt, der opfyldte QC-kriterier

18. november 2026

Først opslået (Faktiske)

19. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • TJ-IRB202611089

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .